XTalks

JULY 31, 2020

HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important? Drive Innovation.

HR 87

HR Containment Scientist Life Science 87

pharmaphorum

MARCH 26, 2025

LEAP HR: Life Sciences East Sara.Scarpinati Wed, 26/03/2025 - 09:00 Bookmark this

HR 52

HR Life Science 52

Pharmaceutical Technology

JUNE 13, 2023

The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen.

HR 245

HR Hormones Trials Protein 245

Pharmaceutical Technology

JULY 1, 2022

The latest filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR clinical trial. Paxlovid received emergency use authorization to treat mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above who are at increased disease progression risk.

HR 264

HR Clinical Development Trials Vaccine 264

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

JANUARY 27, 2023

Daiichi Sankyo president and CEO and Oncology Business global head Ken Keller said: “The approval of Enhertu in HER2 low metastatic breast cancer represents a significant clinical advance for patients in Europe with both HR-positive and HR-negative disease who previously have had limited treatment options in the late-line setting.

HR 235

HR Engineer Antibody Development 235

Pharmaceutical Technology

JULY 8, 2022

The company claimed that the utmost benefit is reported in hormone-receptor positive (HR+) women and those who commence treatment with Nerlynx within a year of receiving trastuzumab-based therapy. In a Phase III ExteNET clinical trial, neratinib offered a 34% decline in the risk of recurrence and a 2.3%

FDA Approval 246

FDA Approval HR Drugs Hormones 246

pharmaphorum

NOVEMBER 28, 2024

Join us in San Francisco, CA this April for LEAP HR: Life Sciences West to network with 200+ senior HR leaders

HR 52

HR Life Science 52

pharmaphorum

NOVEMBER 11, 2024

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR leaders from top Life Sciences organisations for two impactful days of insights and connections tailored to tackle the industry’s unique challenges.

HR 52

HR Life Science 52

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 3, 2024

Navigating regulatory affairs in the biopharma industry requires a skilled talent pool, according to Benjamin James, HR Leader, Asia-Pacific, Cytiva Lifesciences – a global life sciences (biopharma) company. in 2021 to 5.60 […]

HR 183

HR Life Science Clinical Trials Clinical Trials 183

XTalks

MAY 31, 2024

Mercer and Marsh recently released its “ 2024 People Risk Report ,” which highlights critical areas for healthcare HR professionals. Let’s delve into why these points are crucial for healthcare HR professionals, ensuring resilient and effective management of workforces. The collaboration between HR and risk professionals is vital.

HR 52

HR Compliance Containment Development 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

HR 162

HR Marketing Hormones FDA Approval 162

Pharmaceutical Technology

JUNE 9, 2023

The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform. 5 subvariants.

Vaccination 269

Vaccination Vaccine Protein HR 269

BioSpace

MARCH 26, 2024

BioSpace spoke to HR leaders about how they have been supporting companies navigating a challenging economy while meeting the needs of the workforces they support.

HR 59

HR Marketing 59

Medical Xpress

DECEMBER 6, 2022

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 (..)

HR 69

HR Genomics Genome Hormones 69

Pharmaceutical Technology

NOVEMBER 17, 2023

Truqap is approved in combination with Faslodex for HR-positive/HER2-negative breast cancer patients in the US.

FDA Approval 130

FDA Approval HR 130

Pharmaceutical Technology

JULY 28, 2023

Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.

HR 130

HR Drugs 130

Medical Xpress

JANUARY 31, 2025

Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

HR 48

HR FDA Approval Hormones Drugs 48

BioSpace

MAY 5, 2021

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.

HR 56

HR Vaccination Vaccine 56

BioTech 365

NOVEMBER 16, 2020

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading (..)

HR 40

HR 40

XTalks

JANUARY 30, 2025

Novartis has spent three decades advancing breast cancer treatments, focusing on hormone receptor-positive (HR+), HER2-negative breast cancer, the most common subtype. Last year, the FDA approved Kisqali (ribociclib) to reduce the risk of recurrence in HR+/HER2- early breast cancer.

HR 64

HR Hormones FDA Approval Clinical Trials 64

World of DTC Marketing

JANUARY 14, 2022

One of the people I work with has more than 20 years of experience as an HR VP. Yet, when she was contacted about taking over a small companies HR department, she declined because the hiring process consisted of too many interviews over too long a period. Stories about hiring processes within pharma are more like nightmares.

HR 277

HR Production Pharma Companies Marketing 277

BioTech 365

SEPTEMBER 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading →

HR 52

HR 52

Pharmaceutical Technology

JUNE 2, 2023

Data from Novartis ’ Phase III NATALEE trial show that adding Kisqali to endocrine therapy lowered the risk of cancer recurrence by 25% in patients with hormone receptor-positive (HR+)/HER2- early-stage breast cancer (EBC).

HR 130

HR Hormones Trials Drugs 130

Pharmaceutical Commerce

NOVEMBER 17, 2023

The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

HR 52

HR 52

Scienmag

JUNE 30, 2021

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

HR 89

HR Development 89

Pharmaceutical Technology

MARCH 6, 2023

Verzenio along with endocrine therapy (ET) has received approval as an adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) adult patients who are at a high recurrence risk.

FDA Approval 130

FDA Approval HR Hormones Clinical Trials 130

pharmaphorum

NOVEMBER 27, 2024

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours.

HR 98

HR Drugs 98

Pharmaceutical Technology

JUNE 4, 2023

in the placebo arm (hazard ratio [HR]: 0.58). months in the placebo arm (HR: 0.73). At a median duration of follow-up of 25.2 months, the two-year event-free survival (EFS) was 62.4% in the Keytruda arm, versus 40.6% The median EFS was not reached in the Keytruda arm, and was 17 months in the placebo arm.

HR 189

HR FDA Approval Trials Marketing 189

BioTech 365

SEPTEMBER 28, 2021

This HR+/HER2-VE Breast … Continue reading →

HR 40

HR Clinical Trials Clinical Trials Trials 40

Scienmag

DECEMBER 9, 2021

Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.

HR 80

HR Gene Expression Hormones Gene 80

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca.

Antibody 105

Antibody FDA Approval HR Trials 105

The Pharma Data

MARCH 7, 2022

Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Gilead Sciences, Inc.

HR 52

HR Hormones Medicine Trials 52

The Pharma Data

SEPTEMBER 21, 2020

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive. months compared to 14.8

HR 52

HR Hormones Trials 52

BioTech 365

SEPTEMBER 5, 2020

| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading →

HR 40

HR Production 40

Scienmag

SEPTEMBER 20, 2020

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to (..)

HR 45

HR Hormones Drugs Research 45

The Pharma Data

MARCH 25, 2021

months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease. months with IBRANCE plus letrozole versus 11.9 to 0.82; P=0.0002). in the IBRANCE group and 68.0%

HR 52

HR Clinical Trials Clinical Trials Trials 52